Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other Neutral

Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization

Preclinical PNKP inhibitor developer leveraging quantum-AI partnerships to de-risk oncology pipeline amid severe liquidity constraints.

By The Northwire Desk — AI Analysis Jun 16, 2026 · 18:00 ONCO · 0.75 ONCO-INNOVATIONS LIMITED
Executive Summary
  • Onco-Innovations completed a pilot project with Kuano Ltd. utilizing AI and quantum-based computational methods.
  • The collaboration focused on the company's PNKP Inhibitor Technology (ONC010).
  • Deliverables include refined structural hypotheses and a computational framework to guide structure-based optimization and compound prioritization.
  • Next-stage initiatives involve quantum-based QSAR modelling, toxicity mapping, and AI-assisted generative compound design.
  • The stated goal is to accelerate the transition from computational modelling to experimental validation and preclinical development.
Material Impact
  • The release represents a standard, incremental R&D milestone rather than a transformative event.
  • It does not provide clinical data, safety profiles, or efficacy metrics that would alter the risk/reward profile of ONC010.
  • The update does not address the company's critical liquidity position or provide a clear timeline to revenue or clinical trials.
  • Computational modeling advancements are expected in the drug discovery lifecycle and do not constitute a material catalyst for valuation re-rating without subsequent experimental validation.
ONCO · Price
Company Overview
  • Onco-Innovations is a preclinical-stage biotechnology company developing ONC010, a nanoparticle-formulated PNKP inhibitor intended for difficult-to-treat malignancies.
  • The company operates a wholly-owned subsidiary, Inka Health Corp., which is advancing the SynoGraph AI platform for precision oncology and real-world evidence generation.
  • Strategic focus is on IND-enabling studies, manufacturing scale-up, and potential cross-listing on a U.S. exchange to broaden investor access.
  • The business model relies on proprietary IP licensed from the University of Alberta and external partnerships for AI modeling, CMC, and clinical planning.
Read the original news release →

More from ONCO-INNOVATIONS LIMITED

Jun 30, 2026 · 19:00

Preclinical-stage PNKP inhibitor developer pivots to performance-based financing amid liquidity constraints.

Financings Jun 30, 2026 · 18:00

Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010

M&A / Property Jun 26, 2026 · 18:00

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010

Other Jun 26, 2026 · 08:30

Canadian preclinical-stage oncology company developing PNKP inhibitor ONC010 and AI-driven SynoGraph platform.

Other Jun 25, 2026 · 08:30

Preclinical PNKP inhibitor developer burns cash and raises capital while marketing AI oncology partnerships to a niche market.

Other Jun 23, 2026 · 18:00

Preclinical Oncology Developer Secures Polymer Partner to De-Risk ONC010 Manufacturing Ahead of IND Filing

M&A / Property